Clinical trials located in


Tarnów city is located in Poland. Currently, 12 clinical trials are being conducted in this city.

Tarnów, a city in Poland, boasts a rich history dating back to its establishment in 1330. Known for its well-preserved medieval Old Town, Tarnów features a unique Renaissance town hall and a Gothic cathedral housing the Tarnowski family tomb. The city was once home to a significant Jewish community, evidenced by the Bimah of the Old Synagogue. Tarnów also marks the starting point of the Trail of the Eagles’ Nests, leading to Kraków through ancient castles. Its Ethnographic Museum showcases regional Polish culture, highlighting its diverse heritage.

  • CT-EU-00068725

    Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Examining new drug efficiency in avoiding blood clots post knee surgery

    This study is trying to find out how good a medicine named REGN9933 is at preventing blood clots after a person has a single knee replacement. We compare how it works with another medicine called enoxaparin. The main goal of the study is to see if REGN9933 is better at stopping venous clotting after this surgery. The trial will be focused on checking on the chance of bleeding happening after the operation, and if REGN9933 is safe and easy to tolerate for people having knee replacement. The trial will show the new drug’s ability to prevent dangerous clots, and its impact on deep venous thrombosis, which is a clot deep within a vein. Also, it’s essential to understand how it’s absorbed, and how it affects natural clotting mechanisms in the human body and the immune response over time. The study will compare REGN9933 with enoxaparin and another medicine named apixaban.

  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainSwedenUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Study on tezepelumab’s impact on severe asthma in children

    This medical study is testing a new medication, called Tezepelumab, to see if it can help children between the ages of 5 to 12 years old who have severe asthma. The study will take place at multiple centers and will compare the results of kids receiving Tezepelumab with those receiving a placebo, which is a substance that doesn’t contain any medicine. To maintain fairness, the study will be double-blind, meaning both the doctors and patients won’t know who’s taking the real medicine and who’s taking the placebo. The study will take around a year, with an additional 3 months follow-up at the end. If eligible, all children have the chance to receive the active Tezepelumab medication after the study. This is to evaluate the benefits and safety of Tezepelumab as a treatment for severe asthma.

    FranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Investigating lebrikizumab’s safety for severe Atopic Dermatitis patients

    This study investigates the long-term use of Lebrikizumab in adults and teenagers with atopic dermatitis, a serious skin condition. The focus is on determining the safety and effectiveness of Lebrikizumab over a two-year period. Participants who have completed a previous program may join this extension study. The effectiveness of the treatment is measured using several methods, including the EASI score for assessing the severity of the condition, the IGA scale for rating severity, and a scale for measuring itchiness. Additionally, the extent of body coverage by atopic dermatitis is evaluated. Participants are also required to complete a questionnaire about the impact of the skin condition on their daily life.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

  • Comparison of different treatment methods for muscle-invasive bladder cancer

    This trial is designed for patients with muscle-invasive bladder cancer who are either unable to use or decline the use of cisplatin – a commonly used chemotherapy drug. The trial evaluates two treatment methods: surgery alone (cystectomy), and surgery combined with the medications pembrolizumab and/or enfortumab vedotin. The combination therapies happen before and after the surgery. The primary aim is to compare the event-free survival (EFS), meaning time without disease progression or death, in these different approaches. It’s important for potential participants to know they will be randomly assigned a method of treatment for comparison. Medical exams and tests will be conducted to ensure patient safety and monitor progress.

    BelgiumDenmarkFranceGermanyHungaryItalyPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Poland: